NCT00706927View on ClinicalTrials.gov

Effect of Xalacom® (Latanoprost/Timolol) and Combigan® (Brimonidine/Timolol) Fixed Combination on Intraocular Pressure and Ocular Blood Flow in Patients With Primary Open Angle Glaucoma or Ocular Hypertension

NACompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

August 31, 2010

Study Completion Date

September 30, 2010

Conditions
RetinaOcular Physiology
Interventions
DRUG

latanoprost 0.005% + timolol 0,5% fixed combination

1 drop per day and eye for 6 weeks

DRUG

brimonidine 0,2% + timolol 0,5% fixed combination

1 drop twice a day per eye for 6 weeks

Trial Locations (1)

1090

Department of Clinical Pharmacology, Vienna

All Listed Sponsors
lead

Medical University of Vienna

OTHER

NCT00706927 - Effect of Xalacom® (Latanoprost/Timolol) and Combigan® (Brimonidine/Timolol) Fixed Combination on Intraocular Pressure and Ocular Blood Flow in Patients With Primary Open Angle Glaucoma or Ocular Hypertension | Biotech Hunter | Biotech Hunter